AA-group (n = 10) | CP-group (n = 14) | CS-group (n = 5) | P1 | P2 | P3 | P4 | |
---|---|---|---|---|---|---|---|
Clinical findings | |||||||
Age (years) (mean ± SD) | 58.1 ± 14.5 | 62.0 ± 7.3 | 58.0 ± 9.8 | NS | |||
Gender, female, n (%) | 7 (70%) | 11 (76%) | 4 (80%) | NS | |||
Diabetes (+), n (%) | 1 (10%) | 6 (43%) | 0 (0%) | NS | |||
Chronic renal failure (+), n (%) | 2 (20%) | 10 (71%) | 1 (20%) | 0.011‡ | 0.005‡ | NS | NS |
Urotract malignancies (+), n (%) | 2 (20%) | 9 (64%) | 1 (20%) | 0.017‡ | 0.008‡ | NS | NS |
Liver cirrhosis (+), n (%) | 2 (20%) | 9 (64%) | 1 (20%) | 0.017‡ | 0.008‡ | NS | NS |
Hepatocellular carcinoma (+), n (%) | 2 (20%) | 2 (14%) | 0 (0%) | NS | |||
Herbal medicine > 5 years (+), n (%) | 2 (20%) | 3 (21%) | 1 (20%) | NS | |||
Follow-up duration (years) (mean ± SD) | 7.1 ± 3.3 | 7.9 ± 4.3 | 8.2 ± 3.9 | NS | |||
Initial CT findings | |||||||
PC calcification scores (mean ± SD) | 23.5 ± 8.4 | 14.7 ± 10.9 | 11.8 ± 5.7 | 0.046* | NS | NS | NS |
MWT(mm) (mean ± SD) | 10.5 ± 3.4 | 2.3 ± 1.2 | 1.6 ± 0.5 | < 0.001* | < 0.001§ | 0.001§ | NS |
PC segments (mean ± SD) | 4.0 ± 0.8 | 2.4 ± 1.7 | 2.2 ± 1.1 | 0.047* | 0.031§ | 0.028§ | NS |
Pericolic inflammation (+), n (%) | 10 (100%) | 0 (0%) | 0 (0%) | < 0.001‡ | < 0.001‡ | < 0.001‡ | NS |